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critical appraisal.5 7 Moreover, learners have different
learning needs and styles, and these differences must
be reflected in the educational experiences provided.
Just as the intervention has proved difficult to
define, its evaluation has been challenging. Effective
interventions involving evidence based medicine
produce a wide range of outcomes. Changes in knowl-
edge and skills are relatively easy to detect and demon-
strate. Changes in attitudes and behaviours are harder
to confirm. Still more challenging is detecting changes
in clinical outcomes.
By questioning the evidence for evidence based
medicine are we asking the right question? Providing
evidence from clinical research is a necessary but not
sufficient condition for the provision of optimal care.
This has created interest in knowledge translation—the
scientific study of the methods for closing the gap
between knowledge and practice—and the analysis of
barriers and facilitators inherent in this process.8 Propo-
nents of knowledge translation have identified that
changing behaviour is a complex process requiring
comprehensive approaches directed towards patients,
doctors, managers, and policy makers, and providing
evidence is but one component.9 Moreover, it may be
too soon to tell if evidence based medicine changes
clinical performance and outcomes because advocates
think that it requires lifelong learning, and this is not
something that can be measured over the short term.
The BMJ will publish a theme issue on “What’s the
evidence that evidence based medicine changes
anything?” in October 2004. We see this as an
opportunity to reflect on the challenges of practising
and teaching evidence based medicine, highlighting
the work that has been done in this field and providing
an opportunity to point the way forward. We invite
contributions from researchers, patients, health profes-
sionals, policy makers, and other stakeholders, to reach
us by 15 April 2004. Submissions should be made to
www.submit.bmj.com, and the editorial contact is
Giselle Jones (gjones@bmj.com).
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Efficiency, equity, and NICE clinical guidelines
Clinical guidelines need a broader view than just the clinical
The stated purpose of clinical guidelines from theUnited Kingdom’s National Institute for ClinicalExcellence (NICE) is to “help healthcare profes-
sionals and patients make the right decisions about
healthcare in specific clinical circumstances.”1 However,
what constitutes “the right decisions” depends on your
point of view. For individual patients the right decision is
that which maximises their wellbeing, and this is
properly the concern of the clinician. Yet in resource
constrained healthcare systems this will not always coin-
cide with the right decisions for patients in general or
society as a whole, thereby leading to some understand-
able tensions. NICE is a national policy making body
whose responsibility is clearly broader than the
individual patient.2 This wider viewpoint is reflected in
NICE’s technology appraisals by the central role
afforded to cost effectiveness.We argue that themethods
currently used by the NICE clinical guideline pro-
gramme confuse these two viewpoints.
Cost effectiveness analysis allows decision makers
to improve efficiency by spending the limited
healthcare budget on those activities that generate the
greatest health benefits per pound spent.3 Such
efficiency considerations are a key part of NICE
technology appraisals, and NICE’s remit demands that
the same principles of assessing societal wellbeing
should apply to clinical guidelines work.
Clinical guidelines themselves are not a new
concept,4 5 but the NICE clinical guideline programme
is different. Rarely have clinical guidelines been
intended to operate at a national level, incorporate
both clinical and cost effectiveness, and provide
instructions that are mandatory within the NHS
(though, unlike technology appraisals, there is no
requirement for funding to be provided).1 6 Currently,
development of guidelines is commissioned by NICE
from development teams via several national collabo-
rating centres that are largely based at the royal
colleges. These teams produce evidence reviews that
are presented and considered by guideline develop-
ment groups, who then produce the guideline recom-
mendations based on the best available evidence.
Guideline development groups consist substantially
of senior clinicians with special interest in the disease
area.7 Undoubtedly the understanding of clinical
evidence is enhanced by the inclusion of such experts,
but the incentives for members of these groups to
recommend cost effective practices may clash with their
feelings of responsibility to patients and fellow profes-
sionals within this disease area. Each development
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group has to include only one member, a health econo-
mist, whose role is to promote the social viewpoint. The
health economists are often relatively junior, new to the
disease area, and struggling with a lack of economic evi-
dence. For cost effectiveness to underpin NICE guide-
lines in these circumstances is particularly challenging.
Recommendations made within a clinical guideline
are graded according to the strength of the evidence
on which they are based. The highest grades are
afforded to recommendations based on meta-analysis
of randomised controlled trials and the lowest grade to
recommendations based on expert opinion, including
the view of the development group. This classification
also has the effect of reducing the impact of cost effec-
tiveness considerations: health economic evidence is
often sparse in established clinical areas and, where it
does exist, is of variable quality. Rarely is economic evi-
dence based entirely on clinical trials: most economic
analyses require additional data sources or assump-
tions. Members of the guideline development group,
whomay wish to downplay economic evidence, can use
the grading system to this end by claiming that clinical
evidence is of a higher grade. Qualitative evaluation
has identified exactly this tendency in the Netherlands.8
We applaud the efforts of NICE and the guideline
development groups to consider cost effectiveness.
However, the absence of evidence on the cost
effectiveness of guideline recommendations is not an
adequate rationale for issuing guidelines as though they
had no implications for resources. One solution might
be for NICE to delineate clearly the individual
viewpoints of patients and society and allocate expertise
to tasks that are appropriate in the light of this
distinction. In this scenario, collaborating centres would
be commissioned to produce wholly clinical guidelines,
at arm’s length from NICE. This work would provide a
crucially important foundation for subsequent cost
effectiveness assessment undertaken by specialist aca-
demic units. Clinical guidelines that carry the NICE
stamp of approval—and its associated weight in the
NHS—should be produced by guideline appraisal com-
mittees, analogous to NICE technology appraisal
committees, based on consideration of the best available
evidence on clinical and cost effectiveness. A member-
ship that includes expertise in a broad range of clinical
specialties, health economics, public health, and statis-
tics, together with representatives of NHS organisations,
can be expected to make better recommendations that
truly reflect the societal viewpoint that NICE must
reflect.
Such an approach would promote consistency
between the appraisal and guidelines functions of NICE,
make the basis for recommendations transparent, and
avoid accusations that NICE guidelines are wish lists cre-
ated by panels of clinical experts that threaten the
efficient and equitable use of scarce NHS resources.9
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Smoking and blindness
Strong evidence for the link, but public awareness lags
While most people and many patients attend-ing eye clinics recognise many adversehealth hazards of tobacco smoking, they
remain largely unaware of its link with blindness.
Although smoking is associated with several eye
diseases, including nuclear cataractw1 w2 and thyroid eye
disease,w3 the most common cause of smoking related
blindness is age related macular degeneration, which
results in severe irreversible loss of central vision. Cur-
rent treatment options are of only partial benefit to
selected patients. Identifying modifiable risk factors to
inform efforts for prevention is a priority.
A risk factor is generally judged to be a cause of
disease if certain causality criteria are fulfilled.w4 Apply-
ing commonly used criteriaw4 to available evidence
provides strong evidence of a causal link between
tobacco smoking and age related macular degenera-
tion. The strength of association is confirmed in a
pooled analysis of data from three cross sectional stud-
ies, totalling 12 468 participants, in which current
smokers had a significant threefold to fourfold
increased age adjusted risk of age related macular
degeneration compared with never smokers.1 By way
of comparison, although the relative risks associated
with smoking for lung cancer and chronic obstructive
pulmonary disease are in excess of 20, the relative risk
for ischaemic heart disease in men is only 1.6.w5
Consistency of effect is demonstrated as smoking was
the strongest environmental risk factor for age related
macular degeneration across these three different
Additional references w1-w10, a table, and methods appear on
bmj.com
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